CO2022001316A2 - Conjugados peptídicos de citotoxinas como terapéuticos - Google Patents

Conjugados peptídicos de citotoxinas como terapéuticos

Info

Publication number
CO2022001316A2
CO2022001316A2 CONC2022/0001316A CO2022001316A CO2022001316A2 CO 2022001316 A2 CO2022001316 A2 CO 2022001316A2 CO 2022001316 A CO2022001316 A CO 2022001316A CO 2022001316 A2 CO2022001316 A2 CO 2022001316A2
Authority
CO
Colombia
Prior art keywords
cytotoxins
therapeutics
peptide conjugates
conjugates
peptide
Prior art date
Application number
CONC2022/0001316A
Other languages
English (en)
Inventor
Johanna Marie Csengery
Robert A Volkmann
Daniel Richard Marshall
Robert John Maguire
Original Assignee
Cybrexa 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc filed Critical Cybrexa 2 Inc
Publication of CO2022001316A2 publication Critical patent/CO2022001316A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención se refiere a conjugados peptídicos de citotoxinas tales como inhibidores de topoisomerasa I que son útiles para el tratamiento de enfermedades tal como cáncer.
CONC2022/0001316A 2019-07-10 2022-02-09 Conjugados peptídicos de citotoxinas como terapéuticos CO2022001316A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872643P 2019-07-10 2019-07-10
US202063040859P 2020-06-18 2020-06-18
PCT/US2020/041411 WO2021007435A1 (en) 2019-07-10 2020-07-09 Peptide conjugates of cytotoxins as therapeutics

Publications (1)

Publication Number Publication Date
CO2022001316A2 true CO2022001316A2 (es) 2022-05-10

Family

ID=71787212

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001316A CO2022001316A2 (es) 2019-07-10 2022-02-09 Conjugados peptídicos de citotoxinas como terapéuticos

Country Status (17)

Country Link
US (2) US11634508B2 (es)
EP (1) EP3997093A1 (es)
JP (1) JP2022541749A (es)
KR (1) KR20220052918A (es)
CN (1) CN114341162A (es)
AU (1) AU2020309570A1 (es)
BR (1) BR112022000337A2 (es)
CA (1) CA3146560A1 (es)
CL (1) CL2022000038A1 (es)
CO (1) CO2022001316A2 (es)
CR (1) CR20220058A (es)
EC (1) ECSP22010228A (es)
IL (1) IL289658A (es)
MX (1) MX2022000449A (es)
PE (1) PE20220563A1 (es)
TW (1) TW202116778A (es)
WO (1) WO2021007435A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146385A1 (en) 2019-07-10 2021-01-14 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
TW202214230A (zh) 2020-09-30 2022-04-16 大陸商映恩生物製藥（蘇州）有限公司 一種抗腫瘤化合物及其製備方法和應用
JP2024503380A (ja) 2021-01-08 2024-01-25 サイブレクサ ２，インコーポレイテッド コンジュゲート連結部分を調製するための方法
EP4329817A1 (en) 2021-04-29 2024-03-06 Cybrexa 2, Inc. Dosing regimens of peptide conjugates of topoisomerase i inhibitors
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
US20230416331A1 (en) * 2021-11-17 2023-12-28 Cybrexa 4, Inc. Peptide conjugates of peptidic tubulin inhibitors as therapeutics
TW202342025A (zh) * 2022-03-18 2023-11-01 大陸商映恩生物製藥（蘇州）有限公司 Gpc3抗體藥物偶聯物及其用途
KR20230141412A (ko) * 2022-03-29 2023-10-10 주식회사 퓨전바이오텍 친수성 펩타이드를 포함하는 마이셀 및 이의 용도

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
DK0841924T3 (da) 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
KR20000064811A (ko) 1996-04-26 2000-11-06 스즈키 다다시 테트라히드로인돌리진 유도체의 제조법
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
JP4560210B2 (ja) 1998-05-22 2010-10-13 第一三共株式会社 薬物複合体
EP1619210A1 (en) 1998-10-30 2006-01-25 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
ATE284392T1 (de) 1998-11-03 2004-12-15 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
ES2218110T3 (es) 1999-01-11 2004-11-16 Agouron Pharmaceuticals, Inc. Inhibidores triciclicos de poli(adp-ribosa)polimerasas.
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
AU3071801A (en) 1999-12-13 2001-06-18 Eli Lilly And Company Pseudomycin phosphate prodrugs
BR0112417A (pt) 2000-07-13 2003-07-01 Daiichi Seiyaku Co Composições farmacêuticas contendo composto dds
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN102133407A (zh) 2002-03-01 2011-07-27 图兰恩教育基金管理人 治疗剂或细胞毒性剂与生物活性肽的偶联物
JP4359150B2 (ja) 2002-03-20 2009-11-04 ブリストル−マイヤーズ スクイブ カンパニー フルオロオキシインドールのホスフェートプロドラッグ
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
WO2004110498A2 (en) 2003-05-14 2004-12-23 Immunogen, Inc. Drug conjugate composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BRPI0410748B8 (pt) 2003-05-20 2021-05-25 Immunogen Inc compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP5466814B2 (ja) 2003-07-25 2014-04-09 カンサー リサーチ テクノロジー リミテッド 治療用化合物
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
HUE025996T2 (en) 2003-12-01 2016-05-30 Kudos Pharm Ltd Inhibitors of DNA damage repair for the treatment of cancer
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
CA2580833C (en) 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
AU2005286191B2 (en) 2004-09-22 2011-11-17 Cancer Research Technology Ltd. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
CA2591148A1 (en) 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
KR20070120156A (ko) 2005-04-15 2007-12-21 이뮤노젠 아이엔씨 종양에서 이종 또는 혼성 세포 집단의 제거 방법
NZ609752A (en) 2005-08-24 2014-08-29 Immunogen Inc Process for preparing maytansinoid antibody conjugates
CN101316834A (zh) 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
ATE540956T1 (de) 2005-11-08 2012-01-15 Immunogen Inc Verfahren zur herstellung von maytansinol
SI2338487T1 (sl) 2006-01-17 2014-01-31 Abbott Laboratories Kombinacijska terapija z inhibitorji PARP
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
HUE047200T2 (hu) * 2007-08-17 2020-04-28 Purdue Research Foundation PSMA kötõ ligandum-linker konjugátumok és azok alkalmazási módszerei
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
LT2437790T (lt) 2009-06-03 2019-06-10 Immunogen, Inc. Konjugavimo būdai
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
SG10201406805RA (en) 2010-02-12 2014-11-27 Pfizer Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
US9289508B2 (en) 2010-07-13 2016-03-22 University Of Rhode Island Environmentally sensitive compositions and methods of use in the treatment and diagnosis of tumors
AU2011289279B2 (en) 2010-08-13 2016-11-03 University Of Rhode Island Board Of Trustees Liposome compositions and methods of use thereof
CN103269712B (zh) 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
KR20220009505A (ko) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135522A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
KR20230142808A (ko) 2012-10-11 2023-10-11 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
WO2014066002A1 (en) * 2012-10-23 2014-05-01 The Johns Hopkins University Novel self-assembling drug amphiphiles and methods for synthesis and use
WO2014093343A2 (en) 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015095755A1 (en) 2013-12-19 2015-06-25 Seattle Genetics, Inc. Methylene carbamate linkers for use with targeted-drug conjugates
EP3094752A4 (en) 2014-01-16 2017-08-16 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
MY195180A (en) 2014-04-10 2023-01-11 U3 Pharma Gmbh Anti-HER3 Antibody-Drug Conjugate
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
WO2016028689A1 (en) 2014-08-22 2016-02-25 Clovis Oncology, Inc. High dosage strength tablets of rucaparib
PL3110447T3 (pl) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Przeciwciało anty-EGFR i jego zastosowania
RU2711930C2 (ru) 2014-11-19 2020-01-23 Иммуноджен, Инк. Способ получения конъюгатов агента, связывающегося с клетками, и цитотоксического агента
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3380486B1 (en) 2015-11-24 2020-02-19 Theravance Biopharma R&D IP, LLC Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
EP3426301A4 (en) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
EP3442592A4 (en) * 2016-04-13 2019-11-27 Tarveda Therapeutics, Inc. NEUROTENSIN RECEPTOR BINDING CONJUGATES AND ASSOCIATED FORMULATIONS
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
WO2017210608A1 (en) 2016-06-02 2017-12-07 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
EP3491007A4 (en) 2016-07-29 2020-04-22 Memorial Sloan-Kettering Cancer Center RADIO-MARKED LIGANDS FOR TARGETED PET / SPECT IMAGING AND METHODS OF USE THEREOF
IL264845B2 (en) 2016-08-16 2023-09-01 Aist Peptides targeting malignant tumors, conjugates and preparations containing them and their uses
EP3515927A4 (en) 2016-09-22 2020-06-24 Rhode Island Council on Postsecondary Education FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A PH TRIGGERED POLYPEPTIDE
WO2018227132A1 (en) 2017-06-09 2018-12-13 Rhode Island Council On Postsecondary Education Linked and other ph-triggered compounds
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
CN111989137A (zh) 2018-01-05 2020-11-24 赛博克萨1公司 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法
US20200360545A1 (en) 2018-01-12 2020-11-19 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification
EP4249002A3 (en) 2018-05-18 2023-11-22 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
CN114158253A (zh) 2019-01-28 2022-03-08 罗德岛大学理事会 强效细胞毒性化合物的pHLIP®靶向递送
PL3946464T3 (pl) 2019-03-29 2022-12-19 Medimmune Limited Związki i ich koniugaty
CA3146385A1 (en) 2019-07-10 2021-01-14 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics

Also Published As

Publication number Publication date
US11634508B2 (en) 2023-04-25
PE20220563A1 (es) 2022-04-13
ECSP22010228A (es) 2022-05-31
AU2020309570A1 (en) 2022-02-03
TW202116778A (zh) 2021-05-01
KR20220052918A (ko) 2022-04-28
EP3997093A1 (en) 2022-05-18
CR20220058A (es) 2022-07-19
MX2022000449A (es) 2022-04-25
BR112022000337A2 (pt) 2022-04-12
IL289658A (en) 2022-03-01
CA3146560A1 (en) 2021-01-14
WO2021007435A1 (en) 2021-01-14
CL2022000038A1 (es) 2022-08-19
JP2022541749A (ja) 2022-09-27
US20240010755A1 (en) 2024-01-11
CN114341162A (zh) 2022-04-12
US20210009719A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
ECSP22010228A (es) Conjugados peptídicos de citotoxinas como terapéuticos
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
ECSP20069404A (es) Piridazinonas como inhibidoras de parp7
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
CO2022004694A2 (es) Heterociclos bicíclicos como inhibidores de fgfr
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
CO2017011484A2 (es) Inhibidores de bromodominio
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
BR112021024236A2 (pt) Proteínas multiespecíficas
CO2022001315A2 (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
MX2020003862A (es) Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CL2022000457A1 (es) Triazolopirimidinas como inhibidores de a2a/a2b.
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
CO2020016131A2 (es) Agonistas de tlr7
ECSP15001225A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos
CR20140577A (es) Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)